# Reducing Systemic Inflammation in People on Antiretroviral Therapy

> **NCT07030920** · PHASE2 · RECRUITING · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 150 (estimated)

## Conditions studied

- Human Immunodeficiency Virus (HIV)
- Cardiovascular Risk Factor

## Interventions

- **DRUG:** Fostemsavir

## Key facts

- **NCT ID:** NCT07030920
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2028-10
- **Final completion:** 2029-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030920, "Reducing Systemic Inflammation in People on Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07030920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*